Bruker Daltonics to Webcast Q2 Conference Call on August 8, 2002.

Business Editors

BILLERICA, Mass.--(BUSINESS WIRE)--July 26, 2002

Bruker Daltonics Inc. (NASDAQ:BDAL) plans to release its second quarter financial results on Wednesday, August 7, 2002 after the market closes. The company will then host a live streaming-audio CCBN webcast of its operator-assisted earnings conference call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) the following morning. To listen to the webcast, investors can go to www.bdal.com, and then click on the live web broadcast symbol. The on-demand webcast will be available through the company web site for 30 days.

Investors can also listen and participate on the telephone in the US and Canada by calling 888/280-4063 or 706/679-3484 outside North America. Investors should refer to the Bruker Daltonics conference call led by Bruker Daltonics' President and CEO, Dr. Frank Laukien. A telephone replay of the conference call will be available, beginning two hours after the completion of the conference, until September 6, 2002. The toll-free replay will be available by dialing 800/642-1687 in the US and Canada or 706/645-9291 outside North America, and then entering conference ID 5013988.

ABOUT BRUKER DALTONICS

Bruker Daltonics is a leading provider of innovative life science tools based on mass spectrometry. Its substantial investment in research and development allows it to design, manufacture and market a broad array of products intended to meet the rapidly growing needs of a diverse customer base, including pharmaceutical companies, biotechnology companies, proteomics companies, molecular diagnostics companies, academic institutions and government agencies. Bruker Daltonics has diverse technology platforms that integrate automated sample preparation and clean-up, advanced front-end AnchorChip(TM) MALDI targets and API source technology with cutting-edge proprietary MALDI-TOF, MALDI-TOF/TOF, ESI-TOF, ESI-Q-q-TOF, ion trap and FTMS mass analyzers, as well as analysis and bioinformatics software. Bruker Daltonics is also a worldwide leader in supplying mass spectrometry-based systems for substance detection and pathogen identification in security, defense and anti-terrorism applications. Further information is available at: www.bdal.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein.